Drug profile · INN
insulin glargine
ABASAGLAR (PREVIOUSLY ABASRIA)
- US status
- approved
- Patents linked
- 0
- News articles
- 2
Quick answer
insulin glargine (ABASAGLAR (PREVIOUSLY ABASRIA)) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.
Key facts
Related news
FDA Approves LANGLARA Interchangeable Biosimilar to Lantus Insulin - Lannett Company Enters Diabetes Market
FDA approves LANGLARA as interchangeable biosimilar to Lantus insulin glargine, marking Lannett Company's entry into diabetes treatment market through Lanexa Biologics.
Lilly's Foundayo Shows 57% Mortality Reduction in Landmark ACHIEVE-4 Diabetes Trial
Eli Lilly's Foundayo (orforglipron) demonstrates superior cardiovascular outcomes with 57% lower all-cause death risk vs insulin glargine in Phase 3 trial.
Frequently asked questions
What is insulin glargine?
insulin glargine (ABASAGLAR (PREVIOUSLY ABASRIA)) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for insulin glargine?
ABASAGLAR (PREVIOUSLY ABASRIA) is a marketed brand name for insulin glargine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of insulin glargine?
insulin glargine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.